Tax & Penalty25 Jun 2026, 11:39 am
GSK Pharma Receives ₹3.54 Cr Demand Notice from NPPA
AI Summary
GlaxoSmithKline Pharmaceuticals Ltd has received a Demand Notice dated June 24, 2026, from the National Pharmaceutical Pricing Authority (NPPA) for an alleged overcharging of ₹3,54,12,025. The demand includes ₹1,22,91,163 for alleged overcharging and ₹2,31,20,862 as interest. The company states this is due to charging prices higher than fixed/notified for scheduled formulations. GSK Pharma asserts there will be no impact on its financial or operational activities and plans to file an appeal against the demand order.
Key Highlights
- GSK Pharma received a demand notice from NPPA for ₹3.54 Cr.
- Allegation is overcharging on scheduled formulations and interest.
- Company claims no financial or operational impact.
- GSK Pharma intends to appeal the demand order.
Price Impact
More from GLAXO